RecruitingPhase 2NCT05986318

Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease

Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease: A 2x2 Factorial Randomized Phase II Trial Testing N-Acetyl Cysteine and Dexamethasone

Sponsor

David Palma

Enrollment

98 participants

Start Date

Jan 7, 2025

Study Type

INTERVENTIONAL

Conditions

Lung Cancer Interstitial Lung Disease

Summary

In this double-blind phase II randomized controlled trial, patients with lung cancer or ≤2 oligometastatic pulmonary lesions and a concomitant diagnosis of ILD who are planned for radical Radiation Therapy (RT) will be randomized using a 2 x 2 factorial design to oral N-acetylcysteine (NAC) versus placebo, and also to short course corticosteroids versus placebo.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study looks at whether certain medications can reduce breathing symptoms and side effects in people with interstitial lung disease (ILD) — a chronic scarring lung condition — who need radiation therapy for lung cancer or tumors that have spread to the lung. **You may be eligible if...** - You have lung cancer or 1-2 tumors in the lung being treated with high-dose, curative-intent radiation therapy - You have a pre-existing interstitial lung disease (ILD) **You may NOT be eligible if...** - You are not receiving radiation therapy to the lung - You do not have interstitial lung disease - You have certain health conditions that make it unsafe to participate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.